Compare ADMA Biologics Inc (ADMA) vs Banco Bilbao Vizcaya Argentaria SA (BBVA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Banco Bilbao Vizcaya Argentaria SA — how do they compare? ADMA Biologics Inc trades at $9.25 (market cap $2.13B), while Banco Bilbao Vizcaya Argentaria SA trades at $25.28 (market cap $143.90B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 67.6× ADMA Biologics Inc's market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 4.13% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | BBVA | |
|---|---|---|
Market Cap | $2.13B | $143.90B |
Sector | Health | Financials |
52-Week High | $20.38 | $26.14 |
52-Week Low | $7.60 | $14.73 |
Enterprise Value | $2.20B | — |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
BBVA trades at $26.07, up 1.84% today, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 26.51% net income margin and 18.67% ROE, while recent Q1 2026 earnings beat expectations. Positive sentiment is driven by analyst upgrades and news highlighting European bank outperformance and strategic partnerships, though regulatory scrutiny in Spain presents a headwind.
The outlook remains favorable given solid earnings growth, high ROE, and a majority analyst buy rating. Key risks include antitrust investigations and volatile cash flows, but the stock's reasonable P/E of 12.61 and dividend yield offer value. Upside is contingent on sustained loan growth and execution in key markets like Mexico.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →
